healthFDA Approves Genentech's Itovebi Regimen for PIK3CA-Mutated Advanced Breast Cancer
The FDA approved Genentech's Itovebi (inavolisib) combination therapy for adults with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative breast cancer.